Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김충기 | * |
dc.date.accessioned | 2020-04-13T16:30:07Z | - |
dc.date.available | 2020-04-13T16:30:07Z | - |
dc.date.issued | 2020 | * |
dc.identifier.issn | 1738-5520 | * |
dc.identifier.issn | 1738-5555 | * |
dc.identifier.other | OAK-26752 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/253756 | - |
dc.description.abstract | Background and Objectives: We sought to investigate an anti-atherosclerotic and antiinflammatory effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in normoglycemic atherosclerotic rabbit model. Methods: Male New Zealand white rabbits (n=26) were fed with a 1% high-cholesterol diet for 7 weeks followed by normal diet for 2 weeks. After balloon catheter injury, the rabbits were administered with the Dapagliflozin (1mg/kg/day) or control-medium for 8 weeks (n=13 for each group). All lesions were assessed with angiography, optical coherence tomography (OCT), and histological assessment. Results: Atheroma burden (38.51 +/- 3.16% vs. 21.91 +/- 1.22%, p<0.01) and lipid accumulation (18.90 +/- 3.63% vs. 10.20 +/- 2.03%, p=0.047) was significantly decreased by SGLT-2 inhibitor treatment. The SGLT-2 inhibitor group showed lower macrophage infiltration (20.23 +/- 1.89% vs. 12.72 +/- 1.95%, p=0.01) as well as tumor necrosis factor (TNF)-alpha expression (31.17 +/- 4.40% vs. 19.47 +/- 2.10%, p=0.025). Relative area of inducible nitric oxide synthase' macrophages was tended to be lower in the SGLT-2 inhibitor-treated group (1.00 +/- 0.16% vs. 0.71 +/- 0.10%, p=0.13), while relative proportion of Arg1(+) macrophage was markedly increased (1.00 +/- 0.27% vs. 2.43 +/- 0.64%, p=0.04). As a result, progression of atherosclerosis was markedly attenuated in SGLT-2 inhibitor treated group (OCT area stenosis, 32.13 +/- 1.20% vs. 22.77 +/- 0.88%, p<0.01). Mechanistically, SGLT-2 treatment mitigated the inflammatory responses in macrophage. Especially, Toll-like receptor 4/nuclear factor-kappa B signaling pathway, and their downstream effectors such as interleukin-6 and TNF-alpha were markedly suppressed by SGLT-2 inhibitor treatment. Conclusions: These results together suggest that SGLT-2 inhibitor exerts an antiatherosclerotic effect through favorable modulation of inflammatory response as well as macrophage characteristics in non-diabetic situation. | * |
dc.language | English | * |
dc.publisher | KOREAN SOC CARDIOLOGY | * |
dc.subject | Atherosclerosis | * |
dc.subject | Sodium-glucose transporter-2 | * |
dc.subject | Sodium-glucose transporter 2 inhibitors | * |
dc.subject | Macrophages | * |
dc.title | Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 50 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 443 | * |
dc.relation.lastpage | 457 | * |
dc.relation.journaltitle | KOREAN CIRCULATION JOURNAL | * |
dc.identifier.doi | 10.4070/kcj.2019.0296 | * |
dc.identifier.wosid | WOS:000521831400009 | * |
dc.author.google | Lee, Seul-Gee | * |
dc.author.google | Lee, Seung-Jun | * |
dc.author.google | Lee, Jung-Jae | * |
dc.author.google | Kim, Jung-Sun | * |
dc.author.google | Lee, Oh-Hyun | * |
dc.author.google | Kim, Choong-Ki | * |
dc.author.google | Kim, Darae | * |
dc.author.google | Lee, Yong-Ho | * |
dc.author.google | Oh, Jaewon | * |
dc.author.google | Park, Seit | * |
dc.author.google | Jeon, Ok-Hee | * |
dc.author.google | Hong, Sung-Jin | * |
dc.author.google | Ahn, Chul-Min | * |
dc.author.google | Kim, Byeong-Keuk | * |
dc.author.google | Ko, Young-Guk | * |
dc.author.google | Choi, Donghoon | * |
dc.author.google | Hong, Myeong-Ki | * |
dc.author.google | Jang, Yansoo | * |
dc.contributor.scopusid | 김충기(55697727500) | * |
dc.date.modifydate | 20240422141740 | * |